Immunological Implications and Molecular Diagnostics of Genitourinary Cancer updates on recent accomplishments, unifying concepts, and future challenges in the study of tumor-associated immune cells, emphasizing genitourinary cancers. The presence of inflammatory immune cells in human tumors raise a fundamental question: How do cancer cells avoid destruction by immune attack? In principle, tumor development can be controlled by cytotoxic innate and adaptive immune cells, however, as tumors develop from neoplastic tissue to clinically detectable tumors, cancer cells evolve different mechanisms. This book covers research on the immunological implications of genitourinary cancer with a comprehensive view, especially surrounding diagnosis and cellular mechanisms.
1. Chapter 1 Introduction to the molecular aspects and viral therapy of genitourinary tumors - p. 1 2. Chapter 2 Liquid biopsy of exosome markers for molecular diagnosis of genitourinary cancer - p. 5 3. Chapter 3 The molecular mechanism of novel oncogenes dysregulating signaling pathways associated with cervical carcinoma - p. 19 4. Chapter 4 Role of epigenetic factors in cancer progression induced by inactivation of tumor suppressors genes - p. 33 5. Chapter 5 Exosomes as diagnostic and prognostic tools in prostate cancer - p. 45 6. Chapter 6 Adenovirus vectors for vaccination and cancer gene therapy - p. 57 7. Chapter 7 Molecular diagnosis of human oncogenic viruses associated with prostate cancer: Human Papillomavirus and Epstein–Barr virus - p. 77 8. Chapter 8 Molecular characterization of oncogenic biomarkers associated with genitourinary cancers: the case of prostate cancer - p. 99 9. Chapter 9 Diagnostic screening of the microdeleation mutations in the azoospermia factor-gene cluster of the Y chromosome and; prostate cancer among Arabs: toward establishment of gene therapy platform in the region☆☆ In the Book: Genitourinary cancer: Molecular diagnostic immunological implications: genetic aspect and viral therapy. - p. 115 10. Chapter 10 Recent advances in high-risk human papillomavirus genotype relationship with bladder cancer tumor genesis - p. 141 11. Chapter 11 Tumor-associated macrophages in prostate cancer: role in progression and therapy - p. 153 12. Chapter 12 Emerging therapeutic targets of genitourinary tumors - p. 181 13. Chapter 13 Cell–cell differentiation induction: model for cervical cancer - p. 193 14. Chapter 14 The clinical significance of long noncoding RNAs expression in cervical cancers - p. 209 15. Chapter 15 Triple-negative breast cancer and its correlation with viral agents - p. 229 16. Chapter 16 Role of exosomes in bladder cancer diagnosis and therapy - p. 249 17. Chapter 17 Upper urinary tract urothelial cell carcinoma - p. 259 18. Chapter 18 Testicular cancer - p. 275 19. Chapter 19 A comprehensive survey on spectrum of BRCA1 and BRCA2 pathogenic variants in breast and ovarian cancer - p. 285 20. Chapter 20 Molecular and epidemiological characterization of bladder tumors - p. 299 21. Chapter 21 Impact of signaling in the development pathway of genitourinary cancers - p. 311 22. Chapter 22 Prostate cancer: genetic changes and viral-mediated immune regulation - p. 323 23. Chapter 23 Dramatic impact of partial loss of PTEN function on tumorigenesis and progression of prostate cancer - p. 339 24. Chapter 24 Association between glucose consumption and cancer development: prostate cancer and bladder cancer - p. 357 25. Chapter 25 Oncogenic human viruses associated with prostate cancer: molecular epidemiology of Human Papillomavirus and Epstein–Barr virus - p. 373 26. Chapter 26 Genitourinary cancers immune biomarkers: a comprehensive overview - p. 389 27. Chapter 27 The global genomic allelic heterogeneity of the HOXB 13 variants of prostate cancer and gene therapy application for different genealogical lineages of the Y-chromosome haplogroups and haplotypes of STR microsatellites - p. 411 28. Chapter 28 Impact of vitamin D status on breast cancer prognosis - p. 435 29. Index - p. 447
Immunological Implications and Molecular Diagnostics of Genitourinary Cancer updates on recent accomplishments, unifying concepts, and future challenges in the study of tumor-associated immune cells, emphasizing genitourinary cancers. The presence of inflammatory immune cells in human tumors raise a fundamental question: How do cancer cells avoid destruction by immune attack? In principle, tumor development can be controlled by cytotoxic innate and adaptive immune cells, however, as tumors develop from neoplastic tissue to clinically detectable tumors, cancer cells evolve different mechanisms. This book covers research on the immunological implications of genitourinary cancer with a comprehensive view, especially surrounding diagnosis and cellular mechanisms.
1. Chapter 1 Introduction to the molecular aspects and viral therapy of genitourinary tumors - p. 1 2. Chapter 2 Liquid biopsy of exosome markers for molecular diagnosis of genitourinary cancer - p. 5 3. Chapter 3 The molecular mechanism of novel oncogenes dysregulating signaling pathways associated with cervical carcinoma - p. 19 4. Chapter 4 Role of epigenetic factors in cancer progression induced by inactivation of tumor suppressors genes - p. 33 5. Chapter 5 Exosomes as diagnostic and prognostic tools in prostate cancer - p. 45 6. Chapter 6 Adenovirus vectors for vaccination and cancer gene therapy - p. 57 7. Chapter 7 Molecular diagnosis of human oncogenic viruses associated with prostate cancer: Human Papillomavirus and Epstein–Barr virus - p. 77 8. Chapter 8 Molecular characterization of oncogenic biomarkers associated with genitourinary cancers: the case of prostate cancer - p. 99 9. Chapter 9 Diagnostic screening of the microdeleation mutations in the azoospermia factor-gene cluster of the Y chromosome and; prostate cancer among Arabs: toward establishment of gene therapy platform in the region☆☆ In the Book: Genitourinary cancer: Molecular diagnostic immunological implications: genetic aspect and viral therapy. - p. 115 10. Chapter 10 Recent advances in high-risk human papillomavirus genotype relationship with bladder cancer tumor genesis - p. 141 11. Chapter 11 Tumor-associated macrophages in prostate cancer: role in progression and therapy - p. 153 12. Chapter 12 Emerging therapeutic targets of genitourinary tumors - p. 181 13. Chapter 13 Cell–cell differentiation induction: model for cervical cancer - p. 193 14. Chapter 14 The clinical significance of long noncoding RNAs expression in cervical cancers - p. 209 15. Chapter 15 Triple-negative breast cancer and its correlation with viral agents - p. 229 16. Chapter 16 Role of exosomes in bladder cancer diagnosis and therapy - p. 249 17. Chapter 17 Upper urinary tract urothelial cell carcinoma - p. 259 18. Chapter 18 Testicular cancer - p. 275 19. Chapter 19 A comprehensive survey on spectrum of BRCA1 and BRCA2 pathogenic variants in breast and ovarian cancer - p. 285 20. Chapter 20 Molecular and epidemiological characterization of bladder tumors - p. 299 21. Chapter 21 Impact of signaling in the development pathway of genitourinary cancers - p. 311 22. Chapter 22 Prostate cancer: genetic changes and viral-mediated immune regulation - p. 323 23. Chapter 23 Dramatic impact of partial loss of PTEN function on tumorigenesis and progression of prostate cancer - p. 339 24. Chapter 24 Association between glucose consumption and cancer development: prostate cancer and bladder cancer - p. 357 25. Chapter 25 Oncogenic human viruses associated with prostate cancer: molecular epidemiology of Human Papillomavirus and Epstein–Barr virus - p. 373 26. Chapter 26 Genitourinary cancers immune biomarkers: a comprehensive overview - p. 389 27. Chapter 27 The global genomic allelic heterogeneity of the HOXB 13 variants of prostate cancer and gene therapy application for different genealogical lineages of the Y-chromosome haplogroups and haplotypes of STR microsatellites - p. 411 28. Chapter 28 Impact of vitamin D status on breast cancer prognosis - p. 435 29. Index - p. 447
